Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Christian Thiede, Dominik Wolf et al.|Blood|2025Cited by 5
P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)Katja Sockel, Uwe Platzbecker, Anke Mütherig et al.|HemaSphere|2023Cited by 0
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 <scp>DELTA</scp> TrialKatja Sockel, Uwe Platzbecker, Christoph Röllig et al.|American Journal of Hematology|2025Cited by 0